New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
16:13 EDTTGTXTG Therapeutics reports Q2 EPS (36c), consensus (24c)
Reports Q2 license revenue $38,095, consensus $40,000.
News For TGTX From The Last 14 Days
Check below for free stories on TGTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
07:34 EDTTGTXTG Therapeutics announces exercise of license option for TGR-1202
TG Therapeutics announced that it has exercised its option to license the global rights to TGR-1202, the company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A. The company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the company's license option. In exchange for the global license, Rhizen will receive a one-time, upfront cash payment of $4M and approximately 370,000 shares of TG Therapeutics' common stock. TG Therapeutics will receive exclusive worldwide rights, excluding India, for the development and commercialization of TGR-1202 for all indications. Rhizen will be eligible to receive regulatory filing, approval and sales based milestones in the aggregate of approximately $240M, and tiered royalties based on net sales.
September 16, 2014
10:30 EDTTGTXTG Therapeutics capitlal raise unlikely, says Roth Capital
Subscribe for More Information
September 15, 2014
14:10 EDTTGTXTG Therapeutics SPA for CLL study earlier than expected, says Ladenburg
Ladenburg said TG Therapeutics reached an agreement with the FDA regarding a Special Protocol Assessment, or SPA, for a trial of its combo treatment for Chronic Lymphocytic Leukemia, or CLL, "quite ahead" of the firm's December expectation. The firm believes there is a relatively high probability for TG's combo to meet the specified primary endpoint and increased its price target on the stock to $22 from $18.
07:03 EDTTGTXTG Therapeutics announces SPA agreement with FDA for Phase 3 trial of TG-1101
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use